Free Trial
OTCMKTS:QBIO

Q BioMed (QBIO) Stock Price, News & Analysis

Q BioMed logo

About Q BioMed Stock (OTCMKTS:QBIO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
44,335 shs
Market Capitalization
$9 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Receive QBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

QBIO Stock News Headlines

Q BioMed Inc
Orchestra Biomed Reports Q3 2024 Financial Results
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
A Powerful New Tool for Biomedical Research
See More Headlines

QBIO Stock Analysis - Frequently Asked Questions

Q BioMed Inc. (OTCMKTS:QBIO) issued its quarterly earnings data on Wednesday, July, 14th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.04. The firm earned $0.05 million during the quarter.

Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Q BioMed investors own include Intel (INTC), Washington Trust Bancorp (WASH), Cisco Systems (CSCO), Nokia Oyj (NOK), NVIDIA (NVDA), Micron Technology (MU) and NewAge (NBEV).

Company Calendar

Last Earnings
7/14/2021
Today
6/06/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:QBIO
Previous Symbol
NASDAQ:QBIO
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$280 thousand
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
104,178,000
Market Cap
$9 thousand
Optionable
Not Optionable
Beta
2.22
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (OTCMKTS:QBIO) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners